These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 17635237

  • 1. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.
    Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, Loong S, Tao M.
    Eur J Haematol; 2007 Aug; 79(2):132-7. PubMed ID: 17635237
    [Abstract] [Full Text] [Related]

  • 2. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.
    Cancer; 2006 Mar 15; 106(6):1320-5. PubMed ID: 16470607
    [Abstract] [Full Text] [Related]

  • 3. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R.
    Expert Opin Pharmacother; 2009 Oct 15; 10(15):2399-406. PubMed ID: 19761353
    [Abstract] [Full Text] [Related]

  • 4. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.
    Park SC, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, Cho JH, Lee M, Jung HH, Ki SS, Chang YH, Lee SS, Park YH, Lee KH.
    J Med Virol; 2008 Jun 15; 80(6):960-6. PubMed ID: 18428141
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B.
    Haematologica; 2003 Nov 15; 88(11):1296-303. PubMed ID: 14607759
    [Abstract] [Full Text] [Related]

  • 6. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
    Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ.
    J Clin Oncol; 2004 Mar 01; 22(5):927-34. PubMed ID: 14990649
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers.
    Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ.
    Cancer; 2007 Apr 01; 109(7):1360-4. PubMed ID: 17326056
    [Abstract] [Full Text] [Related]

  • 9. Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy.
    Kim YM, Jeong SH, Kim JW, Lee SH, Hwang JH, Park YS, Kim N, Lee JS, Kim HY, Lee DH.
    J Clin Virol; 2011 Aug 01; 51(4):241-5. PubMed ID: 21628103
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N.
    Ann Hematol; 2004 Jan 01; 83(1):58-60. PubMed ID: 14513286
    [Abstract] [Full Text] [Related]

  • 12. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K.
    Bone Marrow Transplant; 2001 Feb 01; 27(4):433-6. PubMed ID: 11313673
    [Abstract] [Full Text] [Related]

  • 13. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
    Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ.
    Breast Cancer Res Treat; 2004 Dec 01; 88(3):209-15. PubMed ID: 15609123
    [Abstract] [Full Text] [Related]

  • 14. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma.
    Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, Chao TC, Yen CC, Chen PM.
    Ann Hematol; 2008 Jun 01; 87(6):475-80. PubMed ID: 18327583
    [Abstract] [Full Text] [Related]

  • 15. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.
    Stroffolini T, Andriani A, Bibas M, Barlattani A.
    Ann Hematol; 2002 Jan 01; 81(1):48-9. PubMed ID: 11807636
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS, Hahn JS, Park SY, Kim Y, Park IH, Lee CK, Cheong JW, Lee ST, Min YH.
    Yonsei Med J; 2007 Feb 28; 48(1):78-89. PubMed ID: 17326249
    [Abstract] [Full Text] [Related]

  • 17. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
    Nakagawa M, Simizu Y, Suemura M, Sato B.
    Am J Hematol; 2002 May 28; 70(1):60-3. PubMed ID: 11994984
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
    Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Takahashi T, Oyama M, Onishi H, Tomita E, Takami T, Imawari M, Moriwaki H.
    Eur J Haematol; 2005 Feb 28; 74(2):158-65. PubMed ID: 15654908
    [Abstract] [Full Text] [Related]

  • 19. High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease.
    Yuan XG, Chen FF, Zhu YM, Hu W, Zhao XY, Jin J.
    Ann Hematol; 2012 Jun 28; 91(6):857-61. PubMed ID: 22186829
    [Abstract] [Full Text] [Related]

  • 20. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
    Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Kim WK, Lee JS, Kang YK.
    J Korean Med Sci; 2003 Dec 28; 18(6):849-54. PubMed ID: 14676442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.